Korro Bio, Inc. (NASDAQ: KRRO) is a Healthcare company (Biotechnology) with a market capitalization of $183M. The Maz Rating grades it against the other companies in its sector.
Korro Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.71, Korro Bio, Inc. trades at 144.1x sales and 2.6x book value. Over the last twelve months it generated about $1M of revenue and a net loss of $129M. It runs a gross margin of 49.8%, an operating margin of -5796.1% and a net margin of -8214.5%. It shows return on equity of -117.1%, return on invested capital of -55.0% and a free cash flow yield of -34.8%. On the balance sheet: a debt-to-equity ratio of 0.47 and a current ratio of 7.30. Over the past 52 weeks the share price ranged from $5.20 to $17.35, with a beta of 2.36.
Korro Bio, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.